2Levy S,Breithardt G,Campbell RWF,et al.On behalf of the working group on arrhythmial of the European Society of Cardiology.Atrial fibrillation;Current knowledge and recommendations for management.Eur Heart J,1998,19:1294-320. 被引量：1
3Prystowsky EN,Benson JD,Woodrow MD,et al.Management of patients with atrial fibrillation:a statement for health care professionals from the subcommittee on electrocardiography and electrophy siology.American Heart Association,Circulation,1996,93:1262-77. 被引量：1
1[1]Laupacis A,Albers G,Dalen J E,et al .Antithrombotic therapy in atrial fibrillation.Chest,1995,108:352s～359s 被引量：1
2[2]Atrial Fibrillation Investigators.Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation:analysis of pooled data from five randomized controlled trials.Arch Intern Med,1994,154:1449～1457 被引量：1
3[3]Vemmos K N,Takis CE,Georgilis K,et al .the Athens stroke registry:results of a five-year hospital-based study.Cerebrovasc Dis,2000,10:133～41 被引量：1
5[5]Falk RH,Podrid PJ.Atrial fibrillation mechanisms and management. 2nd edition Maple Press, 1997.277～98 被引量：1
6[6]Antithrombotic Therapy in Atrial Fibrillation\.The cardiopulmonary and critical care journal.1998,114(5,sup):579s～590s 被引量：1
7[7]Koudstaal PJ.Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks .Cochrane Database Syst Rev,2000,(2): 186～190 被引量：1
8[8]Yamaguchi T.Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation-a multicenter,prospective,randomized trial .Stroke,2000,31:817～21 被引量：1
9[9]Gallus AS,Baker RI,Chong BH,et al.Consensus guidelines for warfarin therapy-recommendations from the Australian Society of Thrombosis and Haemostasis .MJA,2000,172:600～5 被引量：1
10[10]Hylek EM,Skates SJ,Sheehan MA,et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation.N Engl Med J,1996,335:540～6 被引量：1
7Ridker PM, Danielson E, Fonseca FA, et al.. Rosuvastatin to prevent vascular events in men and women with elevat ed C-reactive protein [ J ]. N Engl J Med, 2008,359 ( 21 ) : 2195-207. 被引量：1
8Link A, Ayadhi T, Bohm M, et al. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome [ J ]. Eur Heart J, 2006,27 ( 24 ) : 2945-2955. 被引量：1
9Naji F, Suran D, Kanic V, et al. Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion [ J ]. Med Sci Monit, 2009, 15 (9) :494-498. 被引量：1
